Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Pricing in a softening market
The role of judgement: deciding when to follow the market. This is the second article in a series on pricing in a softening market. In the first art
Pensions Dashboards - handing over the baton
The Pensions Dashboards’ marathon appears to be nearing the final lap. The largest pension schemes, those covering most UK savers, are already connect
The impact of Generative AI on insurance analytics
WTW’s perspective on EIOPA’s 2025 Market-Wide Generative AI Study shows how AI—backed by real insurer use cases—is poised to rewrite the rules of insu

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.